-

Hims & Hers Health, Inc. to Participate at Credit Suisse 30th Annual Healthcare Conference

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE:HIMS), the multi-specialty telehealth platform focused on providing modern personalized health and wellness experiences to consumers, announced today that CEO Andrew Dudum and Chief Medical Officer Patrick Carroll will participate in the Credit Suisse 30th Annual Healthcare Conference with one-on-one meetings throughout the day on Thursday, November 11, 2021.

A fireside chat presentation with Chief Executive Officer Andrew Dudum will be webcast live at 4:20pm ET and will be available on Hims & Hers investor relations website at https://investors.forhims.com/. The webcast will be archived and available for 90 days.

About Hims & Hers Health, Inc.

Hims & Hers is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to primary care, mental health, sexual health, dermatology, and more. Launched in November 2017, the company also offers thoughtfully created and curated health and wellness products. With products and services available across all 50 states and Washington, D.C., Hims & Hers is able to provide access to quality, convenient and affordable care for all Americans. Hims & Hers was founded by CEO Andrew Dudum, Hilary Coles, Jack Abraham and Joe Spector at venture studio Atomic in San Francisco, California. For more information about Hims & Hers, please visit forhims.com and forhers.com.

Contacts

Investors:
Bishop IR
Mike Bishop
(415) 894-9633
mbishop@forhims.com

Industry:

Hims & Hers Health, Inc.

NYSE:HIMS
Release Versions
English
$Cashtags
$HIMS

Contacts

Investors:
Bishop IR
Mike Bishop
(415) 894-9633
mbishop@forhims.com

More News From Hims & Hers Health, Inc.

Hims & Hers Expands GLP-1 Offering in Canada with Generic Semaglutide

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the availability of generic semaglutide through its platform in Canada. This is Hims & Hers’ first international generic GLP-1 offering, demonstrating the company’s ability to meet the unique needs of each global market it serves while continuing its international expansion efforts. Personalized treatment plans are available starting at $149 CAD/month, making...

Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada

TORONTO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the availability of generic semaglutide through its platform for eligible customers in Canada. This makes affordable GLP-1 treatment accessible to Canadians for whom cost has long been a barrier to treatment. For eligible customers, personalised treatment plans are available starting at $149/month CAD. GLP-1 treatments have transformed obesity and metabolic health, with...

Hims & Hers Health, Inc. Prices Upsized $350 Million Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS) today announced the pricing of its offering of $350 million aggregate principal amount of 0.00% convertible senior notes due 2032 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering size was increased from the previously announced of...
Back to Newsroom